Eli Lilly is the latest major pharmaceutical company to bring artificial intelligence (AI) to the healthcare sector. Eli Lilly (LLY -0.40%) is one of the hottest pharmaceutical companies in the world. The company is quickly gaining steam in the weight loss market thanks to its blockbuster drug, Mounjaro, and its sibling treatment, Zepbound. In addition, earlier this month a group of external advisors to the Food and Drug Administration (FDA) endorsed the use of Lilly's Alzheimer's candidate, donanemab. Whil ...

With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.Just look at Eli Lilly (NYSE:LLY).The company is seeing so much demand it’s spending $5.3 billion to make even more Mounjaro and Zepbound. According to The Wall Street Journal, Zepbound alone is generating more than 74,800 prescriptions every week in the U.S. No wonder shares of LLY exploded from a January low of about $580 to $901.26.Helping, demand could rocket even higher with mi ...

Weight loss drugs have taken the pharmaceutical and medical communities by storm. Not only are the companies behind the medications struggling to keep up with global demand, but reports are emerging that the drugs could alleviate health problems beyond obesity. Studies have found that the medications, known as GLP-1 drugs, could help with ailments ranging from sleep apnea to kidney disease.The broad applications have led some analysts to label these medications “miracle drugs.” For the companies behind them ...

Eli Lilly's revenue has climbed, thanks to high demand for its weight loss drugs.The market has been ripe with stock splits in recent times, with companies from tech giant Nvidia to fast-casual restaurant chain Chipotle Mexican Grill announcing them. This occurred after these stocks soared in recent years, in many cases reaching into the thousands of dollars. Companies launch stock splits to lower the price of each individual share, making the shares more affordable for a broader range of investors.Investor ...

In the latest market close, Eli Lilly (LLY) reached $901.26, with a -0.37% movement compared to the previous day. This move lagged the S&P 500's daily gain of 0.16%. Elsewhere, the Dow saw an upswing of 0.04%, while the tech-heavy Nasdaq appreciated by 0.49%.Shares of the drugmaker have appreciated by 11.98% over the course of the past month, outperforming the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22%.Market participants will be closely following the financial results of Eli Lilly in it ...

Here are a few of the highlights from the conference:Companies are also pivoting away from focusing on weight loss alone in trials. Some drugmakers are examining their drugs' potential to treat other health conditions, while others are seeing whether a medication can preserve lean muscle mass in patients while also promoting weight loss.But drugmakers presented treatments that use different approaches than traditional GLP-1s such as Novo Nordisk's popular weight loss injection Wegovy and diabetes counterpar ...

The stock may seem expensive right now, but that may not be the case in a few years.Pharma giant Eli Lilly (LLY 1.63%) has become an unstoppable stock to own lately. Year to date, its share price is up more than 50%. And despite trading at a hefty 130 times earnings, investors continue to buy up more shares of the company. Although it may seem like the stock is approaching a peak, here are two reasons why Eli Lilly's valuation is likely to rise even higher in the future.1. Eli Lilly is still not meeting dem ...

Key TakeawaysEli Lilly is partnering with ChatGPT maker OpenAI to use artificial intelligence to develop new treatments to combat drug-resistant diseases.The companies called drug-resistant diseases one of the "top public health and development threats" in global health.The partnership joins Eli Lilly's other efforts in this area, including investments of millions into funds that promote the creation of antibiotics. Eli Lilly (LLY) said it is partnering with ChatGPT maker OpenAI to use artificial intelligen ...

Eli Lilly and Company (LLY) has seen unparalleled success with tirzepatide, a dual GIP and GLP-1 receptor agonist, which is marketed as Mounjaro for type II diabetes and Zepbound for obesity.Mounjaro was launched in mid-2022, while Zepbound was launched in November 2023. Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly, with demand for weight loss drugs rising rapidly. Tirzepatide is also being developed for other indications, including obstructive sleep a ...

INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape."Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resista ...